Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769572 | 1.00 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| SCHEMBL84795 | 1.00 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL1456828 | 0.97 | SLC7A5 (0.46) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL17099133 | 0.97 | SLC7A5 (0.46) | SLC7A5TSHRDPP4FAPDPP8 | |
| SCHEMBL11789453 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL28500308 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL11789459 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL145865 | 0.84 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL18075532 | 0.82 | TSHR (0.42) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| Hydrochloric Acid SCHEMBL18075258 | 0.82 | TSHR (0.42) | SLC7A5TSHRDPP4DPP7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| EP-2935303-B1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | JANSSEN BIOPHARMA INC (US) | 2021-02-17 | — | — | EP | claimed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | claimed |
| CN-110917205-A | Substituted nucleosides, nucleotides and analogs thereof | 詹森生物制药有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-105408341-B | Substituted nucleosides, nucleotide and the like | 艾丽奥斯生物制药有限公司 | 2019-06-21 | — | — | CN | claimed |
| EP-3421482-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Alios Biopharma, Inc. (US) | 2019-01-02 | — | — | EP | claimed |
| EP-2827875-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA INC (US) | 2018-11-14 | — | — | EP | claimed |
| EP-2794627-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA INC (US) | 2018-09-26 | — | — | EP | claimed |
| EP-2619216-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| WO-2013096680-A1 | SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| WO-2012040127-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | SLC7A5 980/4885TSHR 2346/4885DPP4 1175/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | SLC7A5 1328/4885TSHR 3446/4885DPP4 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.